Sponsor:
Amgen
Code:
NCT06700343
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ocrelizumab (US)
Ocrelizumab (EU)
ABP 692
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations